For more than twenty years, every box of menopause hormone therapy carried a black box warning, the strongest alert the US Food and Drug Administration can attach to a medicine. It named heart disease, breast cancer and probable dementia. Millions of women read it, or were told about it, and decided against treatment. In November 2025 the FDA announced it was removing those warnings, and the labels have been rewritten through 2026. If you were put off hormone therapy by that warning, this is the article explaining what changed and what did not.
The warnings trace back to the Women's Health Initiative, a large trial whose first results landed in 2002 and made headlines worldwide. Prescriptions collapsed almost overnight.
The problem was never that the trial was badly run. It was who was in it. The average participant was 63 years old and more than a decade past menopause. Many were starting hormones for the first time at an age when cardiovascular disease is already established. The results were then applied, through a warning on every box, to a 51-year-old with hot flushes and broken sleep whose situation was not the one that had been studied.
The phrase clinicians use is the timing hypothesis. It holds that the risks and benefits of hormone therapy depend heavily on when you start relative to menopause. Started within about ten years of menopause, and generally under the age of 60, the balance looks considerably more favourable than the old warning implied. Started fifteen or twenty years later, it looks worse.
The FDA's review, which included an expert panel and a public comment period, concluded that the boxed warnings on cardiovascular disease, breast cancer and probable dementia were not supported for the women most likely to be treated, and that the labels should carry age-specific guidance instead.
One warning remains, and it matters. Systemic oestrogen taken on its own, by a woman who still has her uterus, raises the risk of endometrial cancer. That is why oestrogen is combined with a progestogen for women with a uterus. If you have had a hysterectomy, that particular concern does not apply to you.
This is the detail most likely to be lost in coverage of the change, so it is worth stating plainly: the label was narrowed, not cleared.
A removed warning is not a recommendation. It changes the starting point of the conversation, not the answer.
Hormone therapy is not one product. The differences are practical and worth knowing before the appointment.
That last point is the one that helps the most people, because vaginal symptoms, unlike hot flushes, do not improve with time. They tend to worsen, and they are treatable.
A lot of women were refused hormone therapy, or steered away from it, on the basis of the old warning. If that was you, the question is worth reopening, particularly if:
Going back is not awkward. The guidance changed, which is a perfectly good reason to ask again.
Hormone therapy is treatment for the symptoms of menopause and perimenopause: hot flushes and night sweats, sleep that fragments for no obvious reason, vaginal dryness and pain with sex, mood and concentration changes, and the accelerated bone loss that follows the fall in oestrogen.
The reason the warning did real damage is that these symptoms are not trivial and they are not brief. The average duration of hot flushes is measured in years, not months. Many women were told to wait them out with no treatment offered, which is why so much of the perimenopause conversation over the last decade has been about being dismissed rather than about medicine. If you are not sure whether what you are experiencing fits this picture, a structured symptom check is a reasonable place to organise your thinking before an appointment.
Bring specifics. The five questions that get the most useful answers:
Keeping a record of your symptoms before and after starting is more useful than memory. That is precisely what a Health Passport timeline is for, and it turns a vague "I think I am a bit better" into something you and your doctor can read.
The FDA removed boxed warnings on heart disease, breast cancer and probable dementia from menopause hormone therapy, kept the endometrial cancer warning for oestrogen-only therapy in women with a uterus, and replaced the blanket alert with age-specific guidance. That corrects a twenty-year distortion built on a trial whose participants were much older than the women being warned. It does not make hormone therapy right for everyone. If you avoided the conversation because of the warning, the conversation is now worth having on its merits.
This article is for general education and is not a substitute for professional medical advice. Hormone therapy decisions depend on your personal and family medical history and should be made with a qualified clinician.
Millions of adults are being diagnosed with ADHD in their 30s and 40s, especially women missed in childhood. What it looks like, how it differs from anxiety, and what to do next.
The FDA approved orforglipron, sold as Foundayo, in April 2026: a once-daily GLP-1 tablet with no food or water rules. How it compares to the injections, what it costs, and who it suits.
Last winter's severe flu season was driven by the H3N2 subclade K variant. All three strains in this season's vaccine have been updated. What that means for when you get your shot.